Fennec Pharmaceuticals (FENC) Corporate presentation summary

Transforming cancer care with PEDMARK®

• PEDMARK® is the first and only FDA-approved therapy for cisplatin-induced ototoxicity, endorsed in NCCN guidelines for AYA cancer patients.

• Protected by a robust IP portfolio, with U.S. market exclusivity until 2033 and 10-year pediatric use authorization in Europe.

• Global expansion includes partnerships in Europe, Japan, Turkey, and GCC countries.

• Organization has achieved 7 consecutive quarters of revenue growth, reflecting commercial momentum.

Clinical need and impact of cisplatin-induced hearing loss

• Cisplatin is essential in treating various cancers but causes irreversible hearing loss in 60–90% of patients.

• Hearing loss can begin early in treatment and may worsen over time, affecting both children and adults.

• Quality of life is significantly reduced, impacting speech, learning, social development, and emotional well-being.

• Lifetime costs for early-onset severe hearing loss can exceed $1 million, with major productivity and educational impacts.

PEDMARK®: Clinical evidence and guidelines

• PEDMARK® reduces the risk of hearing loss by ~50% without compromising cancer treatment efficacy.

• Recommended by NCCN guidelines as a Category 2A option for AYA patients, supported by two clinical trials.

• Proven safety profile with manageable side effects; not indicated for patients under 1 month or with metastatic cancers.